Timing of the sentinel lymph node biopsy in breast cancer patients receiving neoadjuvant therapy - Recommendations for clinical guidance

详细信息    查看全文

• 作者：Duveken B.Y. Fontein ; Willemien van de Water ; J. Sven D. Mieog ; Gerrit-Jan Liefers ; Cornelis J.H. van de Velde ; ^{c.j.h.van_de_velde@lumc.nl}
• 关键词：Breast cancer ; Sentinel lymph node biopsy ; Axilla ; Neoadjuvant ; Chemotherapy ; Surgery
• 刊名：European Journal of Surgical Oncology (EJSO)
• 出版年：2013
• 出版时间：May, 2013
• 年：2013
• 卷：39
• 期：5
• 页码：417-424
• 全文大小：194 K

文摘

Neoadjuvant chemotherapy (NAC) is an increasingly important component in the treatment of both locally advanced and early-stage breast cancer. With this, a debate on the timing of the sentinel lymph node biopsy (SLNB) has emerged. At the end of the last century, the SLNB was introduced as an axillary staging modality, and this paper aims to further elucidate this issue in the context of NAC. We compiled available data on the SLNB after NAC and provide clinical guidance for timing the SLNB in this context. On the basis of our findings, we recommend that the SLNB can be performed after NAC in all cases. In patients with a clinically node-negative (cN0) status prior to NAC, the SLNB should be performed after NAC, and in case of a histologically confirmed negative SLNB, a completion axillary lymph node dissection (ALND) has no added value and can be omitted. In patients with clinically positive nodal involvement (cN+) prior to NAC, all axillary surgery can also be performed after NAC.